IP Library Granted Patent US 9,017,958
Granted Patent B2
US 9,017,958 · App. 14/193,391 · Granted Apr 28, 2015

Method of simultaneous detection of heparin-induced immunoglobulins types G, A, and M

Inventor: Brian R. Curtis (Milwaukee, WI)
Assignee: BloodCenter Research Foundation, Inc.
G01N33/6854G01N33/86G01N2333/745
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,017,958
App. No.
14/193,391
Granted
Apr 28, 2015
Kind
B2
Abstract

The invention provides a method for detecting heparin-induced antibodies comprising a) binding a PF4-heparin antigen to a solid surface; b) incubating the bound PF4-heparin with a sample comprising heparin-induced antibodies to be detected; c) contacting the sample with at least two labeled secondary antibodies, wherein the secondary antibodies bind to heparin-induced antibodies present in the sample; d) detecting the presence of the labeled secondary antibodies using flow cytometry or a suitable method, wherein the heparin-induced antibodies bound to the secondary antibodies are identified. In one embodiment, the at least two secondary antibodies are anti-human antibodies which specifically bind to heparin-induced antibodies and are selected from the group consisting of Ig, IgG, IgA, and IgM.

Claims (10)

1. A method of detecting heparin-induced thrombocytopenia (HIT) antibodies in a patient comprising:

a) obtaining a serum or plasma sample from a patient suspected of having HIT;

b) obtaining a solid surface to which a PF4/heparin complex has been bound;

c) contacting the patient sample to the bound PF4/heparin complex, wherein HIT antibodies within the patient sample bind to the complex;

d) contacting the bound HIT antibodies with at least a first and a second labeled secondary antibody, wherein the secondary antibody binds to the HIT antibodies bound to the complex and wherein the first antibody and the second antibody are specific for different isotypes selected from the group consisting of anti-Ig, anti-IgG, anti-IgA, and anti-IgM; and

e) detecting the presence of HIT antibody isotypes based on the presence or absence of the label.

2. The method of claim 1 wherein the at least two secondary antibodies are anti-human antibodies selected from the group consisting of anti-Ig, anti-IgG, anti-IgA, and anti-IgM.

3. The method of claim 1 wherein the solid surface is a bead.

4. The method of claim 1 wherein the label is a fluorophore.

5. The method of claim 1 wherein the PF4/heparin complex is prepared using a covalent chemical reaction to bind the heparin molecules to the solid surface.

Assignments (2)
CHANGE OF NAME Recorded Aug 9, 2019
From: BLOODCENTER RESEARCH FOUNDATION, INC.
To: VERSITI BLOOD RESEARCH INSTITUTE FOUNDATION, INC.
Reel/Frame 050018/0715 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 9, 2015
From: CURTIS, BRIAN R.
To: BLOODCENTER RESEARCH FOUNDATION, INC.
Reel/Frame 035116/0238 →
Continuity (2)
Provisional Application 61776959 · Mar 12, 2013
Related Publication 20140315223A1 · Oct 23, 2014